Additionally, IL-6 treatment of normal fibroblasts increased paxillin alignment, while tocilizumab treatment of keloid fibroblasts decreased paxillin alignment, showing that this response was downstream of IL-6 signaling (Fig. 8E–H). This evidence concerns the gene IL6 and keloid.